These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31774463)

  • 1. Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.
    Ornelas-Loredo A; Kany S; Abraham V; Alzahrani Z; Darbar FA; Sridhar A; Ahmed M; Alamar I; Menon A; Zhang M; Chen Y; Hong L; Konda S; Darbar D
    JAMA Cardiol; 2020 Jan; 5(1):57-64. PubMed ID: 31774463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers.
    Syeda F; Holmes AP; Yu TY; Tull S; Kuhlmann SM; Pavlovic D; Betney D; Riley G; Kucera JP; Jousset F; de Groot JR; Rohr S; Brown NA; Fabritz L; Kirchhof P
    J Am Coll Cardiol; 2016 Oct; 68(17):1881-1894. PubMed ID: 27765191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.
    Holmes AP; Saxena P; Kabir SN; O'Shea C; Kuhlmann SM; Gupta S; Fobian D; Apicella C; O'Reilly M; Syeda F; Reyat JS; Smith GL; Workman AJ; Pavlovic D; Fabritz L; Kirchhof P
    Heart Rhythm; 2021 Jul; 18(7):1212-1220. PubMed ID: 33737232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic drug therapy among patients presenting to emergency department with symptomatic atrial fibrillation - a prospective nationwide cohort.
    Penttilä T; Mäkynen H; Hartikainen J; Hyppölä H; Lauri T; Lehto M; Lund J; Raatikainen MJP;
    Scand J Trauma Resusc Emerg Med; 2017 Aug; 25(1):81. PubMed ID: 28810904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antiarrhythmic effect of combining inhibition of Ca²⁺-activated K⁺ (SK) channels and voltage-gated Na⁺ channels in an isolated heart model of atrial fibrillation.
    Kirchhoff JE; Diness JG; Sheykhzade M; Grunnet M; Jespersen T
    Heart Rhythm; 2015 Feb; 12(2):409-18. PubMed ID: 25496982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines-Atrial Fibrillation Registry.
    Field ME; Holmes DN; Page RL; Fonarow GC; Matsouaka RA; Turakhia MP; Lewis WR; Piccini JP;
    Circ Arrhythm Electrophysiol; 2021 Feb; 14(2):e008961. PubMed ID: 33419385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
    Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
    Am J Cardiol; 2015 Feb; 115(3):316-22. PubMed ID: 25491240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65.
    D'Angelo RN; Rahman M; Khanna R; Yeh RW; Goldstein L; Yadalam S; Kalsekar I; Tung P; Zimetbaum PJ
    J Cardiovasc Electrophysiol; 2021 Jun; 32(6):1529-1537. PubMed ID: 33760297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
    Kirchhof P; Engelen M; Franz MR; Ribbing M; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    Basic Res Cardiol; 2005 Mar; 100(2):112-21. PubMed ID: 15696400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ion Channel and Structural Remodeling in Obesity-Mediated Atrial Fibrillation.
    McCauley MD; Hong L; Sridhar A; Menon A; Perike S; Zhang M; da Silva IB; Yan J; Bonini MG; Ai X; Rehman J; Darbar D
    Circ Arrhythm Electrophysiol; 2020 Aug; 13(8):e008296. PubMed ID: 32654503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation.
    Pokushalov E; Romanov A; De Melis M; Artyomenko S; Baranova V; Losik D; Bairamova S; Karaskov A; Mittal S; Steinberg JS
    Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):754-60. PubMed ID: 23748210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
    Guerra F; Hohnloser SH; Kowey PR; Crijns HJ; Aliot EM; Radzik D; Roy D; Connolly S; Capucci A
    Clin Cardiol; 2014 Dec; 37(12):717-24. PubMed ID: 25470298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Comparison of Classes IC and III Antiarrhythmic Drugs as an Initial Rhythm Control Strategy in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study.
    Kipp R; Askari M; Fan J; Field ME; Turakhia MP
    JACC Clin Electrophysiol; 2019 Feb; 5(2):231-241. PubMed ID: 30784696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic management of atrial fibrillation: current therapeutic strategies.
    Lévy S
    Am Heart J; 2001 Feb; 141(2 Suppl):S15-21. PubMed ID: 11174354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study.
    Al-Jazairi MIH; Nguyen BO; De With RR; Smit MD; Weijs B; Hobbelt AH; Alings M; Tijssen JGP; Geelhoed B; Hillege HL; Tieleman RG; Van Veldhuisen DJ; Crijns HJGM; Van Gelder IC; Blaauw Y; Rienstra M;
    Europace; 2021 Sep; 23(9):1359-1368. PubMed ID: 33899093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs.
    Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):292-300. PubMed ID: 25829248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.
    Gulizia M; Mangiameli S; Chiarandà G; Spadola V; Di Giovanni N; Colletti A; Bulla V; Circo A; Pensabene O; Vasquez L; Vaccaro I; Grammatico A;
    Europace; 2006 Apr; 8(4):302-5. PubMed ID: 16627459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of restoration of sinus rhythm by extensive antiarrhythmic drugs in predicting results of catheter ablation of persistent atrial fibrillation.
    Igarashi M; Tada H; Sekiguchi Y; Yamasaki H; Arimoto T; Kuroki K; Machino T; Murakoshi N; Aonuma K
    Am J Cardiol; 2010 Jul; 106(1):62-8. PubMed ID: 20609649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
    Khachatryan A; Merino JL; de Abajo FJ; Botto GL; Kirchhof P; Breithardt G; Stambler B; Abenhaim L; Grimaldi-Bensouda L
    Europace; 2022 Jul; 24(6):899-909. PubMed ID: 34792111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.